News & Events – Page 3 – Sumitovant

Select Company

December 23, 2020Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
December 18, 2020Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
December 18, 2020Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
November 24, 2020Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
November 12, 2020Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
October 21, 2020Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
October 13, 2020Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia
October 07, 2020Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
October 07, 2020Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal
September 29, 2020Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
« Previous 1 2 3 4 5 … 16 Next »